CBM2 is a multi-institutional Center (The University of Kansas, The University of Kansas Medical Center, Louisiana State University, Wake Forest Medical School, and The University of North Carolina-Chapel Hill), and is supported by the Biotechnology Resource Center mechanism from the National Institutes of Health (National Institute of Biomedical Imaging and Bioengineering; NIBIB).
CBM2 vision is to design, manufacture, and deliver new tools to the biomedical community that utilize liquid biopsies for disease detection and management — Precision Medicine. Our vision is being realized through the delivery of innovative and fully automated mixed-scale systems programmed for different disease states.
The Liquid Biopsy/Biomedical Engineering Core at the University of Kansas Medical Center (KUMC) seeks to fill a position of a Research Associate. This person will analyze liquid biopsy markers, which consist of circulating tumor cells, circulating leukemia cells, extracellular vesicles, and cell free DNA, secured from biological fluidic such as blood, plasma etc. The successful candidate will work alongside other scientists to maintain operation of the Core. Candidates must have a Master’s Degree in disciplines such as the physical sciences or engineering. Ph.D. preferred.
The KU Department of Chemistry seeks to fill the postion of Process Engineer. The successful candidate will focus on the design and fabrication of microstructures and nanostructures in a variety of materials, including silicon and plastics. Knowledge in the areas of photolithography, wet/dry etching, thin film deposition, and cleanroom operation are required.
The Center seeks to disseminate its Core Technologies into the research and clinical domains. The Center can accomplish this through a variety of mechanisms and is enthusiastic to discuss this with you. In particular, we can support efforts in such areas as liquid biopsy analyses, and designing and building microfluidic and nanofluidic devices for a variety of application areas.
CBM2 invites researchers (national and international) at all levels and interested in learning more about our core competencies, which include plastic-based microfluidics/nanofluidics and liquid biopsies, to visit our laboratories for extended periods-of-time as part of our visiting scholar program. Due to the geographical distribution of our Center, visiting scholars can select to visit UNC-Chapel Hill, Louisiana State University, or the University of Kansas (the Medical Center or the Lawrence campus).
During your stay, you can directly participate in experiments that match your learning needs. The length of stay is entirely up to the visiting scholar; we have had visiting scholars that have stayed over the summer months or even an entire year. If you are interested, please click on the “Read More” tab below to learn more about this program.
The "Precision Medicine" initiative was announced by President Obama in his January 20th, 2016 State of the Union address. President Obama said he wanted the United States to "lead a new era of medicine, one that delivers the right treatment at the right time."
Rather than the current one-size-fits-all approach, drugs will be tailored to individuals allowing doctors to target the precise form a disease takes in any individual and avoid administering drugs that may be ineffective or even harmful.
CBM2 is making timely and important discoveries for the Precision Medicine initiative by developing state-of-the-art tools that can transition quickly into the clinic to provide diagnostic and prognostic information currently inaccessible to the patient due to limitations in current testing platforms.